Abstract
The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the real world, thus highlighting the possible pharmacoeconomic impact. In clinical trials, it has been shown that rituximab 500 mg twice, performs as well as 1 g twice, 2 weeks apart, in terms of the American College of Rheumatology (ACR)20 and ACR50, but not the ACR70. The choice should always be made after considering that the IMAGE trial has demonstrated similar radiographic progression after the first 6 months, but with less control, with low-dose rituximab in the first 6 months. A possible alternative can be hypothesized.
Highlights
The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the real world, highlighting the possible pharmacoeconomic impact
Since inception it has been observed that rheumatoid arthritis (RA) patients treated with rituximab, positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide autoantibodies (ACPA), obtained more clinical benefits than seronegative patients [1,2,3]
In one patient with idiopathic thrombocytopenic purpura, no B cells were seen in the peripheral blood or in the bone marrow or the spleen 3 months after the final rituximab infusion (375 mg/m2 weekly for 4 weeks) [5]
Summary
The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the real world, highlighting the possible pharmacoeconomic impact. Keyword: Rituximab, Low dose, High dose, Synovial tissue B cell depletion, Peripheral B cell depletion
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
